Bio-Techne
TECH
545 hedge funds and large institutions have $12.4B invested in Bio-Techne in 2022 Q4 according to their latest regulatory filings, with 76 funds opening new positions, 204 increasing their positions, 203 reducing their positions, and 59 closing their positions.
120% more funds holding in top 10
Funds holding in top 10: 5 → 11 (+6)
46% more call options, than puts
Call options by funds: $8.18M | Put options by funds: $5.6M
29% more first-time investments, than exits
New positions opened: 76 | Existing positions closed: 59
2% more funds holding
Funds holding: 536 → 545 (+9)
2% more capital inflows, than outflows
Capital inflows: $775M | Capital outflows: $759M
0% more repeat investments, than reductions
Existing positions increased: 204 | Existing positions reduced: 203
1.75% less ownership
Funds ownership: 96.9% → 95.15% (-1.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$169M |
| 2 |
Select Equity Group
New York
|
+$97.6M |
| 3 |
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$41.6M |
| 4 |
Winslow Capital Management
Minneapolis,
Minnesota
|
+$30.6M |
| 5 |
Handelsbanken Fonder
Stockholm,
Sweden
|
+$27M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$112M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$96.7M |
| 3 |
Renaissance Technologies
New York
|
-$52.8M |
| 4 |
Amundi
Paris,
France
|
-$45.4M |
| 5 |
Fred Alger Management
New York
|
-$35M |
TECH Hedge Fund Activity: Q4 2022 in Review
545 of the 6,241 institutional investors tracked by Wall St. Rank reported a position in Bio-Techne (TECH) for Q4 2022, worth a combined $12.4B — up 15% from $10.8B a quarter earlier.
Buyers outnumbered sellers: 76 funds opened new TECH positions and 59 closed out — a net gain of 17 holders — while 204 added to existing stakes and 203 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $169M. The largest seller was BlackRock, cutting an estimated $112M.
- 545 institutional investors held Bio-Techne (TECH) as of Q4 2022, up from 536 in Q3 2022.
- Funds reported $12.4B of Bio-Techne stock for Q4 2022, up 15% quarter-over-quarter.
- 76 funds opened new Bio-Techne positions in Q4 2022 and 59 closed out, a net change of +17 holders.
- The largest Bio-Techne buyer in Q4 2022 was Morgan Stanley, an estimated $169M added.
- The largest Bio-Techne seller in Q4 2022 was BlackRock, an estimated $112M sold.
Based on aggregated 13F filings for Q4 2022.